Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

Core Insights - Femasys Inc. has initiated patient enrollment in the FINALE pivotal trial for FemBloc, a non-surgical permanent birth control solution, following FDA approval based on positive clinical data [1][2] - FemBloc is already being commercialized in Europe and other countries, aiming to provide a safer and more accessible alternative to surgical sterilization [1][2] Company Overview - Femasys is focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a broad portfolio of patented therapeutic and diagnostic products [4] - The company has received regulatory approvals for FemBloc in Europe, the UK, and New Zealand, with plans for strategic partnerships to enhance commercialization [5][6] FINALE Trial Details - The FINALE trial is a prospective, multi-center, open-label study assessing the safety and effectiveness of FemBloc, with an initial roll-in enrollment of 50 women completed [3] - The primary endpoint of the trial is the pregnancy rate after one year of using FemBloc, with an interim analysis planned after 300 participants complete one year [3] Product Features - FemBloc utilizes a patented delivery system to place a proprietary blended polymer into the fallopian tubes, forming natural scar tissue for permanent occlusion [2] - This non-surgical method aims to reduce procedural risks and healthcare costs associated with traditional surgical sterilization [2]